French Society of Radiation Oncology (SFRO), 2024

Authors

‍Jessica Selz ¹, Thomas Leroy ², Alexandra Suissa ¹, Rémi Bourdais ¹, Adrien Paix ³, Élodie Nouhaud ⁴, Carlota Ganzarain ⁴, Oscar Berges ¹, Caroline Daveau ¹, Angélique Ducteil ⁵, Jérôme Chamois ⁶, Yohan Pointreau ⁷, Éric Deutsch ⁸.

‍

Affiliation

‍1. Institut de Cancérologie de Seine-et-Marne, Jossigny ; 2. Centre de Cancérologie Les Dentelières, Valenciennes ; 3. Centre de Radiothérapie de Bobigny ; 4. Resilience, Paris ; 5. Centre d’Oncologie et de Radiothérapie du Pays Basque, Bayonne ; 6. Institut de Cancérologie et Radiothérapie Bretilien, Rennes ; 7. Centre de Cancérologie de la Sarthe, Le Mans ; 8. Gustave Roussy, Villejuif.

‍

Introduction

ePROs (electronic Patient-Reported Outcomes) used in medical Remote Patient Monitoring (RPM) have proven their efficacy through Phase III randomized controlled clinical trials^[1-4]. These studies highlight clinical and organizational benefits, notably:

• Better symptom management,
• Improved quality of life,
• Increased relative dose intensity,
• Reduction in hospitalizations,
• Prolongation of overall survival.

In 2022, ESMO (European Society for Medical Oncology) issued its recommendations regarding the integration of medical remote monitoring into routine practice during anti-cancer treatments^[5].

However, its application in the field of radiotherapy remains largely unexplored. This study aims to evaluate patient adherence to this model of care as well as its clinical benefits.

‍

Poster presented at the 2024 Congress of the French Society of Radiation Oncology (SFRO).

‍

Sources

1. Mir O, Ferrua M, Fourcade A, et al. Digital remote monitoring plus usual care versus usual care in patients treated with oral anticancer agents: the randomized phase 3 CAPRI trial. Nat Med.2022;28(6):1224-1231.

‍

2. Basch E, Schrag D, Henson S, et al. Effect of Electronic Symptom Monitoring on Patient-Reported Outcomes Among Patients With Metastatic Cancer: A Randomized Clinical Trial. JAMA. 2022;327(24):2413-2422.

‍

3. Basch E, Deal AM, Kris MG, et al. Symptom Monitoring With Patient-Reported Outcomes During Routine Cancer Treatment: A Randomized Controlled Trial. J Clin Oncol. 2019 Feb20;37(6):528.

‍

4. Basch E, Deal AM, Dueck AC, et al. Overall Survival Results of a Trial Assessing Patient-Reported Outcomes for Symptom Monitoring During Routine Cancer Treatment. JAMA.2017;318(2):197-198.

‍

5. Di Maio M, Basch E, Denis F, et al. The role of patient-reported outcome measures in the continuum of cancer clinical care: ESMO Clinical Practice Guideline. Ann Oncol. 2022;33(9):878-892. doi:10.1016/j.annonc.2022.04.007